Tourette syndrome: Gene expression as a tool to discover drug targets

Neurotherapeutics

Volumn 7, Issue 3, 2010, Pages 302-306

  Liao, Isaac H ^a   Sharp, Frank R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene expression; Microarrays; Pharmacology; Tourette syndrome

Indexed keywords

ARIPIPRAZOLE; CLONIDINE; CLOZAPINE; GENOMIC DNA; GUANFACINE; MESSENGER RNA; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GILLES DE LA TOURETTE SYNDROME; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; DNA MICROARRAY; DRUG DEVELOPMENT; GENETICS; PROCEDURES; TOURETTE SYNDROME;

DRUG DISCOVERY; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TOURETTE SYNDROME;

EID: 77954903756     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.05.007     Document Type: Article

References (62)

1. Diagnostic and statistical manual of mental disorders (DSM-IV-TR) 2007, American Psychiatric Assoc, Arlington, VA. 4th ed.
2. Swain J.E., Scahill L., Lombroso P.J., King R.A., Leckman J.F. Tourette syndrome and tic disorders: a decade of progress. J Am Acad Child Adolesc Psychiatry 2007, 46:947-968.
3. Müller N. Tourette's syndrome: clinical features, pathophysiology, and therapeutic approaches. Dialogues Clin Neurosci 2007, 9:161-171.
4. Singer H.S. Tourette's syndrome: from behaviour to biology. Lancet Neurol 2005, 4:149-159.
5. Kremer H.P.H. What's wrong with Tourette syndrome?. Parkinsonism Relat Disord 2007, 13(Suppl 3):S385-S386.
6. Pauls D.L., Raymond C.L., Stevenson J.M., Leckman J.F. A family study of Gilles de la Tourette syndrome. Am J Hum Genet 1991, 48:154-163.
7. Kano Y., Ohta M., Nagai Y., Pauls D.L., Leckman J.F. A family study of Tourette syndrome in Japan. Am J Med Genet 2001, 105:414-421.
8. Walkup J.T., LaBuda M.C., Singer H.S., et al. Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. Am J Hum Genet 1996, 59:684-693.
9. Hebebrand J., Klug B., Fimmers R., et al. Rates for tic disorders and obsessive compulsive symptomatology in families of children and adolescents with Gilles de la Tourette syndrome. J Psychiatr Res 1997, 31:519-530.
10. Eapen V., Pauls D.L., Robertson M.M. Evidence for autosomal dominant transmission in Tourette's syndrome. United Kingdom cohort study. Br J Psychiatry 1993, 162:593-596.
11. Price R.A., Kidd K.K., Cohen D.J., Pauls D.L., Leckman J.F. A twin study of Tourette syndrome. Arch Gen Psychiatry 1985, 42:815-820.
12. Miranda D.M., Wigg K., Kabia E.M., et al. Association of SLITRK1 to Gilles de la Tourette syndrome. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:483-486.
13. Barr C.L., Wigg K.G., Sandor P. Catechol-O-methyltransferase and Gilles de la Tourette syndrome. Mol Psychiatry 1999, 4:492-495.
14. Verkerk A.J.M.H., Mathews C.A., Joosse M., et al. CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. Genomics 2003, 82:1-9.
15. Kajiwara Y., Buxbaum J.D., Grice D.E. SLITRK1 binds 14-3-3 and regulates neurite outgrowth in a phosphorylation-dependent manner. Biol Psychiatry 2009, 66:918-925.
16. Poliak S., Gollan L., Martinez R., et al. Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels. Neuron 1999, 24:1037-1047.
17. Alarcón M., Abrahams B.S., Stone J.L., et al. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet 2008, 82:150-159.
18. Arking D.E., Cutler D.J., Brune C.W., et al. A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. Am J Hum Genet 2008, 82:160-164.
19. Poot M., Beyer V., Schwaab I., et al. Disruption of CNTNAP2 and additional structural genome changes in a boy with speech delay and autism spectrum disorder. Neurogenetics 2010, 11:81-89.
20. Barr C.L., Wigg K.G., Sandor P. Catechol-O-methyltransferase and Gilles de la Tourette syndrome. Mol Psychiatry 1999, 4:492-495.
21. Deng H., Le W.D., Xie W.J., Jankovic J. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand 2006, 114:400-402.
22. Fabbrini G., Pasquini M., Aurilia C., et al. A large Italian family with Gilles de la Tourette syndrome: clinical study and analysis of the SLITRK1 gene. Mov Disord 2007, 22:2229-2234.
23. Cavallini M.C., Di Bella D., Catalano M., Bellodi L. An association study between 5-HTTLPR polymorphism, COMT polymorphism, and Tourette's syndrome. Psychiatry Res 2000, 97:93-100.
24. Belloso J.M., Bache I., Guitart M., et al. Disruption of the CNTNAP2 gene in a t(7;15) translocation family without symptoms of Gilles de la Tourette syndrome. Eur J Hum Genet 2007, 15:711-713.
25. Scharf J.M., Moorjani P., Fagerness J., et al. Lack of association between SLITRK1var321 and Tourette syndrome in a large family-based sample. Neurology 2008, 70:1495-1496.
26. Giller E.L., Young J.G., Breakefield X.O., et al. Monoamine oxidase and catechol-O-methyltransferase activities in cultured fibroblasts and blood cells from children with autism and the Gilles de la Tourette syndrome. Psychiatry Res 1980, 2:187-197.
27. Keen-Kim D., Mathews C.A., Reus V.I., et al. Overrepresentation of rare variants in a specific ethnic group may confuse interpretation of association analyses. Hum Mol Genet 2006, 15:3324-3328.
28. Pauls D. An update on the genetics of Gilles de la Tourette syndrome. J Psychosom Res 2003, 55:7-12.
29. Singer H.S., Giuliano J.D., Hansen B.H., et al. Antibodies against human putamen in children with Tourette syndrome. Neurology 1998, 50:1618-1624.
30. Swedo S.E., Leonard H.L., Garvey M., et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998, 155:264-271.
31. Singer H.S., Hong J.J., Yoon D.Y., Williams P.N. Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls. Neurology 2005, 65:1701-1707.
32. Corbett B.A., Mendoza S.P., Baym C.L., Bunge S.A., Levine S. Examining cortisol rhythmicity and responsivity to stress in children with Tourette syndrome. Psychoneuroendocrinology 2008, 33:810-820.
33. Bloch M.H., Leckman J.F. Clinical course of Tourette syndrome. J Psychosom Res 2009, 67:497-501.
34. Canitano R., Vivanti G. Tics and Tourette syndrome in autism spectrum disorders. Autism 2007, 11:19-28.
35. Peterson B.S., Thomas P., Kane M.J., et al. Basal ganglia volumes in patients with gilles de la Tourette syndrome. Arch Gen Psychiatry 2003, 60:415-424.
36. Peterson B.S., Skudlarski P., Anderson A.W., et al. A functional magnetic resonance imaging study of tic suppression in Tourette syndrome. Arch Gen Psychiatry 1998, 55:326-333.
37. Baym C.L., Corbett B.A., Wright S.B., Bunge S.A. Neural correlates of tic severity and cognitive control in children with Tourette syndrome. Brain 2008, 131:165-179.
38. Srour M., Lespérance P., Richer F., Chouinard S. Psychopharmacology of tic disorders. J Can Acad Child Adolesc Psychiatry 2008, 17:150-159.
39. Gaffney G.R., Perry P.J., Lund B.C., et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 2002, 41:330-336.
40. Rang H. Pharmacology 2003, 129. Churchill Livingstone, Edinburgh. 5th ed.
41. Leckman J.F., Goodman W.K., Anderson G.M., et al. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 1995, 12:73-86.
42. Sands S., Dickerson D., Morris S., Chronwall B. Dopamine D2 receptor stimulation alters G-protein expression in rat pituitary intermediate lobe melanotropes. Endocrine 1997, 6:325-333.
43. Schena M., Heller R.A., Theriault T.P., et al. Microarrays: biotechnology's discovery platform for functional genomics. Trends Biotechnol 1998, 16:301-306.
44. Debouck C., Goodfellow P.N. DNA microarrays in drug discovery and development. Nat Genet 1999, 21(1 Suppl):48-50.
45. Geschwind D.H., Konopka G. Neuroscience in the era of functional genomics and systems biology. Nature 2009, 461:908-915.
46. Lit L., Enstrom A., Sharp F.R., Gilbert D.L. Age-related gene expression in Tourette syndrome. J Psychiatr Res 2009, 43:319-330.
47. Lit L., Gilbert D.L., Walker W., Sharp F.R. A subgroup of Tourette's patients overexpress specific natural killer cell genes in blood: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:958-963.
48. de Haas A.H., van Weering H.R.J., de Jong E.K., Boddeke H.W.G.M., Biber K.P.H. Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol Neurobiol 2007, 36:137-151.
49. Volterra A., Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 2005, 6:626-640.
50. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998, 392:565-568.
51. Ransohoff R.M., Kivisakk P., Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003, 3:569-581.
52. Martino D., Dale R.C., Gilbert D.L., Giovannoni G., Leckman J.F. Immunopathogenic mechanisms in Tourette syndrome: A critical review. Mov Disord 2009, 24:1267-1279.
53. Ogata H., Goto S., Sato K., et al. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 1999, 27:29-34.
54. Blake J.A., Harris M.A. The Gene Ontology (GO) project: structured vocabularies for molecular biology and their application to genome and expression analysis. Curr Protoc Bioinformatics 2002 Nov, Chapter 7:Unit 7.2.
55. Holm S. A Simple Sequentially Rejective Multiple Test Procedure. Scand Stat Theory Appl 1979, 6:65-70.
56. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat 1995, 57:289-300.
57. Fare T.L., Coffey E.M., Dai H., et al. Effects of atmospheric ozone on microarray data quality. Anal Chem 2003, 75:4672-4675.
58. Branham W.S., Melvin C.D., Han T., et al. Elimination of laboratory ozone leads to a dramatic improvement in the reproducibility of microarray gene expression measurements. BMC Biotechnol 2007, 7:8.
59. Byerly S., Sundin K., Raja R., et al. Effects of ozone exposure during microarray posthybridization washes and scanning. J Mol Diagn 2009, 11:590-597.
60. Ayroles J.F., Gibson G. Analysis of variance of microarray data. Meth Enzymol 2006, 411:214-233.
61. Keren H., Lev-Maor G., Ast G. Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet 2010, 11:345-355.
62. Okoniewski M.J., Miller C.J. Comprehensive analysis of affymetrix exon arrays using bioconductor. PLoS Comput Biol 2008, 4:e6.